The global pseudomonas aeruginosa treatment market is expected to cross USD 7.5 billion by 2027. It can achieve growth at ra CAGR of 7% over the forecast peiod. It stood at USD 1 billion in 2018. Development of suitable vaccines for fighting non-communicable and hereditary diseases is likely to drive the market demand. For instance, antibody tests for testing the strength of pseudomonas aeruginosa in cystic fibrosis can used to determine the strength of vaccines.